Company Overview and News
A tax change may prompt the conglomerate to buy out minority unit holders of Boardwalk Pipeline. Some are worried about the price.
LGCYP LGCYO CQP LNG COMM BWP L BPL EXAS PDCO AM BRK.A SRLP TCP LGCY
The week started strong, with MLPs up 1.6% Monday, but then followed up with 4 straight negative days, culminating in a big Friday selloff (-2.6%). Friday was the MLP Index's worst day since March 19th, just a few days after the FERC ruling. It was also the worst week for the index since that same week in March. Unlike that week, there wasn't any big midstream news that led to the drop. The action this week was more related to the macro (i.
ETP.PRC CQP DCP XOM PSX PAGP ENB WGP CEQP AM USAC WMB AMGP PAA D CNXM ENB SRE.PRA TCP ETP SRE DM NRP TRGP
Increasing growth in natural gas production from the Marcellus and Utica shales in Pennsylvania, Ohio, and West Virginia is currently constrained by the lack of available takeaway pipeline capacity to move it to new markets.
AM EQM WES
Between May 18 and May 25, the SPDR S&P Oil & Gas Exploration & Production ETF (XOP) fell 5.3%—the second-largest decline among the major energy subsector ETFs that we discussed in the previous part of this series.
AM EQM RMP
In recent weeks there’s been growing discussion about the future of MLPs (see Are MLPs Going Away?). Although the prospects for U.S. energy infrastructure are very good, the need for growth capital has exposed the limitations of the MLP investor base. Not everyone agrees. Stacey Morris of Alerian provided a thoughtful assessment (see Are MLPs Really Disappearing?), and concluded that MLPs would remain the dominant corporate form in the sector.
KMI.WS EPD UAL TEP SEP TEGP AM WPZ EQM KMI.PRA KMI WMB OKE MMP EEP PAA KMR CVB TRP TCP ETP JPM SEMG NS TRGP KMRFZ
The following slide deck was published by Antero Midstream Partners in conjunction with their 2018 Q1 earnings call.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
am_Current Folio_10Q Table of Contents
Phillips 66 Partners (PSXP) is a midstream MLP owned by one of the largest US refiners, Phillips 66 (PSX). It’s expected to post a 61% YoY (year-over-year) EBITDA (earnings before interest, tax, depreciation, and amortization) growth in 1Q18 compared to 1Q17. Growth is expected to be driven mainly by the contribution from expansion projects placed into service. For 2018, analysts expect EBITDA growth of 41.
Antero Midstream Partners (AM) is a midstream MLP involved in natural gas gathering, natural gas compression, and water-related midstream services in the Appalachian region. It’s expected to post 30.7% YoY (year-over-year) growth in 1Q18 compared to 1Q17. For 2018, Wall Street analysts expect its EBITDA (earnings before interest, tax, depreciation, and amortization) to increase 36.5%. Its strong growth is expected to be driven by its strong gathering and water throughput volumes.
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to AM / Antero Midstream Partners LP on message board site Silicon Investor.
as of ET